go-v.orgdoi

Radiation therapy following a positive sentinel lymph node biopsy: A radiation oncologist’s dilemma

Zaker Hamid Rana, Kruti Patel, Katherine H. R. Tkaczuk, Susan Beth Kesmodel, Steven Joel Feigenberg · Applied Radiation Oncology · 2015

  • DOI 10.37549/aro1063
  • Publisher OpenAlex
  • Type article
  • Issued 2015

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Applied Radiation Oncology · OpenAlex · article · 2015

Abstract

36 n APPLIED RADIATION ONCOLOGY www.appliedradiationoncology.com March 2015 CASE SUMMARY SD, a 40-year-old African-American female, presented with a palpable mass in the left breast. Her work-up led to the diagnosis of an infiltrating ductal carcinoma. The patient underwent a partial mastectomy and sentinel lymph node biopsy, with pathology demonstrating a 2.8 cm high-grade carcinoma that was ER(-), PR(-), HER2(-); 1 of the 2 sampled sentinel lymph nodes demonstrated metastatic disease. Thereafter, she received 4 cycles of dose-dense Adriamycin and Cytoxan, followed by weekly paclitaxel.

Following chemotherapy, she received radiotherapy at an outside institution to the intact breast to a total dose of 5040 cGy, followed by a boost of 1400 cGy to the tumor bed for a total dose of 6440 cGy. Unfortunately, she palpated a mass below her clavicle, which was biopsied and confirmed recurrent disease 3 years following therapy completion. She was treated with induction chemotherapy and had a good response. She then presented to our cancer center for consideration for further local therapy. The patient underwent a completion axillary lymph node dissection, which demonstrated multiple residual lymph nodes involved with cancer.

She was subsequently offered radiation therapy to the axilla and supraclavicular fossa, which included an area of overlap from her prior radiation fields. To minimize risk of late effects from radiation, a hyperfractionated schedule was employed (1 Gy BID to 50 Gy with 6 hours between treatments). The patient is currently free of disease one year following radiation treatement. This case illustrates an important point regarding the adoption of the results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial in all patients with involved sentinel lymph nodes.

Open the resolved locator · 10.37549/aro1063

Metadata licence: OpenAlex metadata (CC0)